Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
5
|
pubmed:dateCreated |
1985-2-5
|
pubmed:abstractText |
Since intermittent cardioplegic reperfusion during an ischemic period may reduce the ischemic stress of the heart at least by lowering myocardial temperature, we compared the post-ischemic recovery of the dog heart following cardioplegia and subsequent continuous ischemia of 1 X 300 minutes at 22 +/- 1 degree C (model 1) and following cardioplegia and subsequent 3 X 100 minutes of ischemia at 17 +/- 1 degree C with intermittent 4-minute cardioplegic reperfusion every 100 minutes (model 2). The parameters of post-ischemic recovery were the cardiac O2 consumption per beat at work (MVO2-E0): HR), the stability of cardiac rhythm, the left ventricular content of high-energy phosphates, and ultrastructure. Solution HTK with a magnesium concentration of 9 mM/L, in clinical use up to the beginning of 1984, resulted in a significantly better post-ischemic recovery in model 1, despite about 40% lesser ischemic stress in model 2. A reduction of Mg concentration from 9 to 4 mM/l, as in the HTK solution clinically tested since February 1984, did facilitate the post-ischemic recovery in model 1 as indicated by the stability of cardiac rhythm but led to a significant improvement of all parameters of recovery in model 2. Moreover, recovery in model 2 after reduced Mg was also clearly better than in model 1 corresponding to the lesser ischemic stress. The parameters myocardial O2 consumption (MVO2) and potassium loss during HTK perfusion containing 9 and 4 mM/l, respectively, gave indications of specific membrane labilizing effects of Mg in the cardioplegic solution HTK.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Adenine Nucleotides,
http://linkedlifedata.com/resource/pubmed/chemical/Adenosine Triphosphate,
http://linkedlifedata.com/resource/pubmed/chemical/Anti-Arrhythmia Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Histidine,
http://linkedlifedata.com/resource/pubmed/chemical/Magnesium,
http://linkedlifedata.com/resource/pubmed/chemical/Phosphocreatine,
http://linkedlifedata.com/resource/pubmed/chemical/Quinine
|
pubmed:status |
MEDLINE
|
pubmed:month |
Oct
|
pubmed:issn |
0171-6425
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
32
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
271-6
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:6083614-Adenine Nucleotides,
pubmed-meshheading:6083614-Adenosine Triphosphate,
pubmed-meshheading:6083614-Animals,
pubmed-meshheading:6083614-Anti-Arrhythmia Agents,
pubmed-meshheading:6083614-Dogs,
pubmed-meshheading:6083614-Dose-Response Relationship, Drug,
pubmed-meshheading:6083614-Electrocardiography,
pubmed-meshheading:6083614-Heart Arrest, Induced,
pubmed-meshheading:6083614-Heart Conduction System,
pubmed-meshheading:6083614-Histidine,
pubmed-meshheading:6083614-Magnesium,
pubmed-meshheading:6083614-Myocardium,
pubmed-meshheading:6083614-Oxygen Consumption,
pubmed-meshheading:6083614-Phosphocreatine,
pubmed-meshheading:6083614-Quinine
|
pubmed:year |
1984
|
pubmed:articleTitle |
Different effects of cardioplegic solution HTK during single or intermittent administration.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|